Abstract:Normally siRNA has to be chemically stabilized in therapeutic applications. It is a challenge to obtain optimal stabilizing effects while maintaining full silencing activity due to a lack of understanding of how different chemical modifications would influence the efficacy of siRNA. In the current study, the effect of single 2'-sugar modifications was profiled across the length of the siRNA guide strand. This led to the surprising finding that a single 2'-OMe modification at position 14 of the siRNA guide strand substantially compromised its gene-silencing activity in a manner that was independent of the nucleotide identity at this site or the sequence context around it. We found that modification at position 14 of the siRNA guide strand reduced its RNA-induced silencing complex (RISC) loading tremendously, whereas the loading of the siRNA sense strand was only marginally affected. When comparing the silencing potency of 14th position-modified siRNA (transfected at 16.7 nM) and native control (transfected at 1 nM) at equivalent Ago2 loading levels, the silencing potency of modified siRNA was much lower, even lower than the level of native siRNA transfected at 0.1 nM. These data indicated that modification at position 14 of the siRNA guide strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation. Using a computational modeling approach, we demonstrated an intimate interaction between the 14th nucleotide of guide strand and the amino acid Q675 in the AGO protein, which is located in a highly conserved loop of PIWI domain. In addition to gaining insights into siRNA-AGO interactions, this study of structure-activity relationship further established a general principle for siRNA modification in siRNA drug development.

Optimization in Chemical Modification of Single-Stranded Sirna Encapsulated by Neutral Cytidinyl/Cationic Lipids

Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of Sirnas

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Chemical Modifications Influence the Number of siRNA Molecules Adsorbed on Gold Nanoparticles and the Efficiency of Downregulation of a Target Protein

Chemically Modified Sirnas and Their Conjugates

RNA Interference with Chemically Modified Sirna.

Lipid-Modified Aminoglycoside Derivatives for in Vivo Sirna Delivery

Asymmetric Sirna: New Strategy to Improve Specificity and Reduce Off-Target Gene Expression.

Single Modification at Position 14 of Sirna Strand Abolishes Its Gene‐silencing Activity by Decreasing Both RISC Loading and Target Degradation

Novel Cationic Lipid with Reduction-Responsive Cleavable Hydrophobic Tail for Sirna Delivery

Biodegradable Stearylated Peptide with Internal Disulfide Bonds for Efficient Delivery of Sirna in Vitro and in Vivo.

Delivery Pathway Regulation of 3′,3″-Bis-peptide-sirna Conjugate Via Nanocarrier Architecture Engineering

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

Studies on Aminoisonucleoside Modified Sirnas: Stability and Silencing Activity.

A Novel Gemini-Like Cationic Lipid For The Efficient Delivery Of Sirna

Ph-Sensitive Nanomicelles for High-Efficiency Sirna Delivery in Vitro and in Vivo: an Insight into the Design of Polycations with Robust Cytosolic Release

Efficient Cytosolic Delivery Of Sirna Using Hdl-Mimicking Nanoparticles

Polycation Liposomes Combined with Calcium Phosphate Nanoparticles As a Non-Viral Carrier for Sirna Delivery

Feasibility of Crgd Conjugation at 5-Antisense Strand of Sirna by Phosphodiester Linkage Extension

Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference

Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.